В. В. Бредер - Researcher Profile

Publications

2 shown

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn , Baek‐Yeol Ryoo , Philippe Merle +17 more

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...

2019 Journal of Clinical Oncology 1737 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 8,201
Institution: Russian Cancer Research Center NN Blokhin

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6244-4294

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.